XLRN Acceleron Pharma Inc.

28.37
+0  (1%)
Previous Close 28.16
Open 28.32
Price To book 4.77
Market Cap 1.09B
Shares 38,394,000
Volume 179,517
Short Ratio 6.59
Av. Daily Volume 384,606

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ACE-083
Charcot-Marie-Tooth disease (CMT)
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Open label initial data due late 2017, with randomized part of trial to be initiated in 2018.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 preliminary data due 2H 2017.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes
  2. Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : April 4, 2017
  3. Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar
  4. Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  5. Acceleron Pharma Price Target Raised by Leerink
  6. Acceleron reports 4Q loss
  7. Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results
  8. Acceleron to Participate in Two Healthcare Investor Conferences in March
  9. Acceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017
  10. Acceleron to Participate in Two Healthcare Investor Conferences in February
  11. Top Insider Buys Highlight for Week of Jan. 6
  12. Acceleron Outlines Corporate Goals and Priorities for 2017
  13. Former CEO of Finish Line Inc. (FINL) Sells Shares as Underperformance Persists; Other Notable Insider Transactions
  14. Acceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
  15. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
  16. Celgene, Acceleron Launch Blood Disorder Study (CELG)
  17. Acceleron, Celgene Present Myelodysplastic Syndromes Data
  18. Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
  19. Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : December 1, 2016
  20. Hedge Funds Are Buying Acceleron Pharma Inc (XLRN)